Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 172-183

  Kon Kim, Tae ^a   Gore, Steven D ^a   Zeidan, Amer M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; ASPARAGINASE; AZACITIDINE; BORTEZOMIB; CYTARABINE; DAUNORUBICIN; DECITABINE; ENTINOSTAT; GEMTUZUMAB OZOGAMICIN; GSK 2879552; IDARUBICIN; MOCETINOSTAT; OXYGENASE INHIBITOR; PANOBINOSTAT; PINOMETOSTAT; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; DNA METHYLATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; HISTONE MODIFICATION; HUMAN; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

EID: 84937402257     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.04.003     Document Type: Review

References (105)

1. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381:484-495.
2. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. J Natl Compr Cancer Netw 2012, 10:984-1021.
3. Yates J.W., Wallace H.J., Ellison R.R., Holland J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973, 57:485-488.
4. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
5. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6-21.
6. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
7. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
8. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
9. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Rev Cancer 2012, 12:599-612.
10. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002, 3:415-428.
11. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
12. Melki J.R., Vincent P.C., Clark S.J. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia 1999, 13:877-883.
13. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 2001, 97:2823-2829.
14. Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
15. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
16. Conway O'Brien E., Prideaux S., Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014, 2014:103175.
17. Marcucci G., Metzeler K.H., Schwind S., et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012, 30:742-750.
18. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
19. Thol F., Damm F., Ludeking A., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
20. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
21. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
22. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
23. Weissmann S., Alpermann T., Grossmann V., et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
24. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
25. Moran-Crusio K., Reavie L., Shih A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
26. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
27. Fathi A.T., Sadrzadeh H., Borger D.R., et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012, 120:4649-4652.
28. Janin M., Mylonas E., Saada V., et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2014, 32:297-305.
29. DiNardo C.D., Propert K.J., Loren A.W., et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013, 121:4917-4924.
30. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
31. Rakheja D., Konoplev S., Medeiros L.J., Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol 2012, 43:1541-1551.
32. Pratcorona M., Abbas S., Sanders M.A., et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012, 97:388-392.
33. Schnittger S., Eder C., Jeromin S., et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013, 27:82-91.
34. Abdel-Wahab O., Adli M., LaFave L.M., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
35. Gelsi-Boyer V., Brecqueville M., Devillier R., Murati A., Mozziconacci M.J., Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012, 5:12.
36. Metzeler K.H., Becker H., Maharry K., et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011, 118:6920-6929.
37. Shen Y., Zhu Y.M., Fan X., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011, 118:5593-5603.
38. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
39. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
40. Oki Y., Issa J.P. Epigenetic mechanisms in AML-a target for therapy. Cancer Treat Res 2010, 145:19-40.
41. Jackson-Grusby L., Laird P.W., Magge S.N., Moeller B.J., Jaenisch R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A 1997, 94:4681-4685.
42. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010, 28:1069-1078.
43. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
44. Saunthararajah Y., Sekeres M., Advani A., et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest 2015, 125:1043-1055.
45. Hambach L., Ling K.W., Pool J., et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 2009, 113:2715-2722.
46. Guo Z.S., Hong J.A., Irvine K.R., et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006, 66:1105-1113.
47. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
48. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin Oncol 2006, 24:3895-3903.
49. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
50. Lubbert M., Ruter B.H., Claus R., et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97:393-401.
51. Kantarjian H.M., Thomas X.G., Dmoszynska A., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
52. Navada S.C., Steinmann J., Lubbert M., Silverman L.R. Clinical development of demethylating agents in hematology. J Clin Invest 2014, 124:40-46.
53. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
54. Yang G., Khalaf W., van de Locht L., et al. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML. Ann Hematol 2004, 83:329-330.
55. Bots M., Verbrugge I., Martin B.P., et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 2014, 123:1341-1352.
56. Garcia-Manero G., Yang H., Bueso-Ramos C., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
57. Schaefer E.W., Loaiza-Bonilla A., Juckett M., et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009, 94:1375-1382.
58. Odenike O.M., Alkan S., Sher D., et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008, 14:7095-7101.
59. Kuendgen A., Knipp S., Fox F., et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005, 84(Suppl 1):61-66.
60. Kuendgen A., Schmid M., Schlenk R., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
61. Bug G., Ritter M., Wassmann B., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725.
62. Raffoux E., Chaibi P., Dombret H., Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90:986-988.
63. Garcia-Manero G., Assouline S., Cortes J., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
64. Gojo I., Jiemjit A., Trepel J.B., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109:2781-2790.
65. Giles F., Fischer T., Cortes J., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006, 12:4628-4635.
66. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361-6369.
67. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
68. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
69. Blum W., Klisovic R.B., Hackanson B., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
70. Walter R.B., Medeiros B.C., Gardner K.M., et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica 2014, 99:54-59.
71. Ravandi F., Alattar M.L., Grunwald M.R., et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121:4655-4662.
72. Fili C., Malagola M., Follo M.Y., et al. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res 2013, 19:3297-3308.
73. Kantarjian H.M., Giles F.J., Greenberg P.L., et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010, 116:3163-3170.
74. Welch J.S., Klco J.M., Gao F., et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol 2011, 86:796-800.
75. Sekeres M.A., Tiu R.V., Komrokji R., et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012, 120:4945-4951.
76. Blum W., Schwind S., Tarighat S.S., et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
77. Garcia-Manero G., Tambaro F.P., Bekele N.B., et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012, 30:2204-2210.
78. Issa J.P., Garcia-Manero G., Huang X., et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2014, 121:556-561.
79. Prebet T., Sun Z., Figueroa M.E., et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 2014, 32:1242-1248.
80. Griffiths E.A., Choy G., Redkar S., Taverna P., Azab M., Karpf A.R. SGI-110 DNA methyltransferase inhibitor oncolytic. Drug Future 2013, 38:535-543.
81. Kantarjian H.M., Jabbour E., Yee K., et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Blood 2013, Paper presented at American Society Hematology Annual Meeting and Exposition; December 7-10, 2013. New Orleans, LA, USA.
82. Ueda K., Yoshimi A., Kagoya Y., et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci 2014, 105:512-519.
83. Zhou J., Bi C., Cheong L.L., et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011, 118:2830-2839.
84. Xu B., On D.M., Ma A., et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015, 125:346-357.
85. Momparler R.L., Cote S., Momparler L.F., Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenet 2014, 6:19.
86. Fiskus W., Wang Y., Sreekumar A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
87. Nguyen A.T., Taranova O., He J., Zhang Y DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011, 117:6912-6922.
88. Bernt K.M., Zhu N., Sinha A.U., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
89. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
90. Klaus C.R., Iwanowicz D., Johnston D., et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Therapeut 2014, 350:646-656.
91. Liu W., Deng L., Song Y., Redell M. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PloS One 2014, 9:e98270.
92. Sarkaria S.M., Christopher M.J., Klco J.M., Ley T.J. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 2014, 21:178-184.
93. Filippakopoulos P., Picaud S., Mangos M., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
94. Stewart H.J., Horne G.A., Bastow S., Chevassut T.J. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med 2013, 2:826-835.
95. Dawson M.A., Gudgin E.J., Horton S.J., et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014, 28:311-320.
96. Luo Z., Lin C., Shilatifard A. The super elongation complex (SEC) family in transcriptional control. Nature Rev Mol Cell Biol 2012, 13:543-547.
97. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
98. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
99. Wyspianska B.S., Bannister A.J., Barbieri I., et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia 2014, 28:88-97.
100. Mould D.P., McGonagle A.E., Wiseman D.H., Williams E.L., Jordan A.M. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med Res Rev 2015, 35:586-618.
101. Harris W.J., Huang X., Lynch J.T., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
102. Schenk T., Chen W.C., Gollner S., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18:605-611.
103. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013, 122:2877-2887.
104. Emadi A., Jun S.A., Tsukamoto T., Fathi A.T., Minden M.D., Dang C.V. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 2014, 42:247-251.
105. Elhammali A., Ippolito J.E., Collins L., Crowley J., Marasa J., Piwnica-Worms D. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 2014, 4:828-839.